Questcor: From Orphan Drug To Orphan Stock?
Blaise Zerega can't fathom an 1,800% price hike. Russ Mitchell's examination yesterday of why Questcor Pharmaceuticals raised the price of a drug used to treat infantile epilepsy from $1,600 per vial to $23,000 per vial helps set the stage for Congressional hearings tomorrow. But in the meanwhile, the company's share price is already taking a hit, down 9% to $4.57 as of this posting. What if it QCOR shares eventually fell 1,800%? Instant karma, anyone?
. □
. □






